Compare FMC Corp (FMC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs TG Therapeutics Inc — how do they compare? FMC Corp trades at $8.3 (market cap $1.39B), while TG Therapeutics Inc trades at $54.95 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 5.9× FMC Corp's market cap, and FMC Corp pays a 3.59% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FMC Corp for 68 Days and TG Therapeutics Inc for 16 Days on average.
| FMC | TGTX | |
|---|---|---|
Market Cap | $1.39B | $8.16B |
Volume | 4,145,979 | 1,735,121 |
Sector | Basic Materials | Health |
52-Week High | $30.63 | $59.06 |
52-Week Low | $8.44 | $26.94 |
Typical Hold Time | 68 Days | 16 Days |
Enterprise Value | $5.19B | $8.37B |
Dividend Yield | 3.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC trades at $8.36, down 8.03% in the past 24 hours, reflecting bearish technical signals and weak profitability. The company reported a net loss of -$2.24B in 2025, with negative margins and declining revenue. Recent news includes a regulatory filing for rimisoxafen in Brazil and a minority equity investment by Tessenderlo Group. Cash flow trends show volatility, with 2025 net cash flow positive at $227M but driven by financing activities.
The outlook remains challenging due to persistent losses and high debt, though analyst consensus suggests upside with a $14.60 price target. Key risks include execution on deleveraging, cyclical industry pressures, and competitive threats. Investment opportunity hinges on successful turnaround efforts and new product approvals.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
